Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1623 1672 1673 1691 1693
This examiner grants 72% of resolved cases
SHIAO, YIH-HORNG is an examiner in Tech Center 1600 and Art Unit 1621. The data shows 972 resolved cases for this examiner. The allowance rate is 72.5 percent, which indicates the proportion of grants among resolved applications. Practitioners can use this 72.5 percent figure to evaluate the probability of a successful outcome. The count of 972 resolved cases provides a basis for understanding the examiner's historical trends in this art unit.
The interview lift is 75.9 percent. This metric represents the difference in the allowance rate when an interview is conducted compared to the overall rate of 72.5 percent. An interview lift of 75.9 percent suggests that direct communication with the examiner is associated with an exceptionally large increase in the probability of receiving a grant. Practitioners should prioritize scheduling interviews to address specific rejections or to clarify technical aspects of the claims. This 75.9 percent lift is a critical factor in developing a prosecution strategy.
The median days to allowance is 877. This number represents the middle value of the time taken from the start of prosecution to the issuance of a patent. A median of 877 days provides a timeline for applicants to manage their expectations regarding the duration of the process. The combination of the 72.5 percent allowance rate and the 877-day pendency characterizes the current prosecution environment. These metrics help in planning the resources and time required for applications assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18742823 | BROMODOMAIN INHIBITORS | Non-Final OA | AbbVie Inc. |
| 18750008 | BACTERIAL DERIVED NANOCELLULOSE TEXTILE MATERIAL | Non-Final OA | DePuy Synthes Products, Inc. |
| 18757757 | METHODS FOR MAKING POLYSACCHARIDE-PROTEIN CONJUGATES | Non-Final OA | Merck Sharp & Dohme LLC |
| 17986361 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Non-Final OA | Agilent Technologies, Inc. |
| 18283408 | METHODS AND COMPOSITIONS FOR TREATING CANCER THERAPY-INDUCED NEUTROPENIC FEVER AND/OR GVHD | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18507851 | TUMOR IMMUNOTHERAPY | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18687149 | COMPOSITION FOR ENHANCING IMMUNOGENICITY | Non-Final OA | TORAY INDUSTRIES, INC. |
| 18469530 | EXPANDING THE CHEMICAL SUBSTRATES FOR GENETIC CODE REPROGRAMMING | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18666922 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | Non-Final OA | BOEHRINGER INGELHEIM VETMEDICA GMBH |
| 18594627 | SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | Non-Final OA | Boehringer Ingelheim Vetmedica GmbH |
| 18043254 | RNA STORAGE METHOD | Final Rejection | KAO CORPORATION |
| 18681728 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Non-Final OA | CORNELL UNIVERSITY |
| 18714279 | HYALURONIC ACID POWDER | Non-Final OA | Kewpie Corporation |
| 18733430 | METHOD FOR SEPARATING COMPONENTS USING SUPERCRITICAL FLUID CHROMATOGRAPH | Non-Final OA | OSAKA UNIVERSITY |
| 18692298 | PHARMACEUTICAL COMPOSITION AND A PROCESS TO PREPARE THE SAME | Non-Final OA | GODAVARI BIOREFINERIES LIMITED |
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | Non-Final OA | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy